A Phase 2 interventional study of Low Metformin and Metformin in Type 2 Diabetes Mellitus, sponsored by NuSirt Biopharma. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-27.
Sponsored by NuSirt Biopharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 154th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 23 in phase 2, and was the 193rd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 16 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
NuSirt Biopharma is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
NuSirt Biopharma has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to demonstrate that leucine in combination with a low does of metformin can serve as an adjunct to diet and exercise to improve blood glucose levels in type 2 diabetic subjects. This study will compare three doses of a leucine-metformin combination to the standard metformin dose in controlling blood glucose levels in type 2 diabetic patients.
This is a randomized, 4-week, active-controlled, double-blind study to evaluate the effect of various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy on glycemic control. In this study, standard metformin therapy will be defined as 1000 g/day for Day 1 to Day 14 and then escalated to 1700 g/day for Day 15 to Day 28. Subjects meeting all inclusion criteria and no exclusion criteria will be randomized to one of four treatment arms.
The primary objective of the study is to evaluate the change in fasting plasma glucose from Baseline (Day 1) to Week 4 (Day 28) in subjects receiving various fixed-dose combinations of leucine and metformin compared to standard metformin monotherapy. Secondary objectives will also assess changes in baseline-corrected plasma glucose and insulin area under the concentration curves from baseline to day 28 and changes in insulin secretory rates as assessed during a 3-hour meal tolerance test. Finally the effects of gastrointestinal symptoms will be assessed by subject questionnaires.
The study will include a total of 3 periods: screening or washout of current diabetic monotherapy, a pre-treatment period to ensure subjects will be compliant, and a treatment period of 4 weeks, with the first dosing of medication on day 1 of the study. Each day blood glucose readings will be measured and recorded by patients. Three-hour standardized meal tests will be performed at Baseline (Day 1) and at Study Termination (Day 28). In addition, two, 7-day continuous glucose assessments will be conducted, as well as two seven point glucose profiles. Patients will also be asked about any gastrointestinal side effects they experience.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lipid-lowering agents Anti-hypertensive medications Thyroid replacement therapy Non-steroidal anti-inflammatory agents
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 41.7 mg of metformin
Drug: Low Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 83.3 mg of metformin
Drug: Mid Metformin
3 capsules BID with each capsule containing 366.7 mg L-Leucine and 166.7 mg of metformin
Drug: High Metformin
3 Capsules BID each containing 166.7 mg of metformin with dose escalation to 283.3 mg capsules BID (1,700 mg/Day) at Day 14.
Drug: Metformin
1100 mg L Leucine in combination with 125 mg of Metformin BID
Also known as: Metformin, Leucine, L-Leucine
500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
1100 mg of Leucine in combination with 250 mg Metformin BID
Also known as: Metformin, Leucine, L-Leucine
1100 mg of Leucine in combination with 500 mg Metformin BID
Also known as: Metformin, Leucine, L-Leucine
Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr
The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.
Time frame: 0, 15min, 30min, 45min, 1hr, 1.5hrs, 2hrs, 2.5hrs and 3 hrs
Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC)
The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.
Time frame: Baseline, Day 28
Change in Fasting Plasma Glucose
Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.
Time frame: Baseline, Day 28
Change in Hemoglobin A1c (HbA1c)
Changes in HbA1c which is a marker of long-term glucose control was assessed.
Time frame: Baseline, Day 28
Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)
Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.
Time frame: Baseline, Day 28
Change In 7-Point Glucose Profiles
The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., \[(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)\]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.
Time frame: Baseline, Day 7, Day 21, Day 28
Plasma Insulin Absolute and Incremental Meal Tolerance Test Area Under the Curve (AUC) 0-2hr
Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.
Time frame: Baseline,Day 28
Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration
Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.
Time frame: Baseline, Day 28
Subjects meeting all inclusion criteria and no exclusion criteria were randomized to one of four treatment arms in the ratio of 1:1:1:1 (A:B:C:D). The randomization was stratified by fasting plasma glucose (≥126 mg/dL to \<200 mg/dL, and ≥200 mg/dL to ≤220 mg/dL), as well as metformin experience. Yes/No history of abdominal side effects.
| Milestone | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Started | 24 | 25 | 24 | 23 |
| Completed | 18 | 24 | 21 | 19 |
| Not completed | 6 | 1 | 3 | 4 |
| Withdrew: Adverse event | 5 | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 |
| Withdrew: Treatment discontinuation | 0 | 0 | 1 | 0 |
The primary endpoint for NS 0100 01 was the absolute plasma glucose AUC (0-3 hr) change from Day 1 to Day 28.
| mg*hrs/dL | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Change From Baseline to Day 28 in Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr | -18.005 ± 142.8374 | -45.029 ± 114.6701 | -64.010 ± 146.0917 | -141.848 ± 194.9300 |
The baseline incremental (baseline-subtracted) glucose AUC0-3h was evaluated for treatment differences at baseline.
| mg*hrs/dL | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Change From Baseline to Day 28 in Incremental Plasma Glucose Area Under the Curve (AUC) | -2.338 ± 60.2834 | -17.614 ± 93.1243 | -23.061 ± 64.6290 | -29.604 ± 86.1126 |
Change in fasting plasma glucose for the fixed dose leucine and metformin combination treatments A, B and C was evaluated.
| mg/dL | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Change in Fasting Plasma Glucose | -6.8 ± 36.91 | -9.7 ± 26.50 | -13.4 ± 38.55 | -36.0 ± 47.36 |
Changes in HbA1c which is a marker of long-term glucose control was assessed.
| percent | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Change in Hemoglobin A1c (HbA1c) | 0.11 ± 0.448 | -0.16 ± 0.485 | -0.01 ± 0.442 | -0.23 ± 0.607 |
Effect on insulin sensitivity across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment.
| HOMA units | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Change in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR) | -0.31 ± 1.010 | -0.14 ± 0.548 | 0.11 ± 0.958 | -0.18 ± 1.017 |
The meal induced glucose change in pre-meal and post-meal glucose were measured 7 times during the day. Subjects self-monitored blood glucose (preprandial and postprandial) concentrations at least 7 times, including before and 1 to 2 hours after breakfast, lunch, dinner, and snacks). For each study day, the pre-meal values from the 7 point test for each subject were averaged to generate a single pre-meal glucose value. Similarly, for each study day the post-meal values from the 7-point test for each subject were averaged to generate a single post-meal glucose value. The average change from baseline (i.e., \[(Mean Pre/Post-meal value at Day 28 - Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 21- Mean Pre/Post-meal value at Baseline) + (Mean Pre/Post-meal value at Day 7- Mean Pre/Post-meal value at Baseline)\]/ 3) over multiple time points listed in Time Frame. The mean pre-meal and post-meal values for baseline, day7, day 21 and day28 were used for comparison.
| mg/dL | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| 28 day change in Pre-meal Glucose Level | -6.50 ± 32.343 | -8.96 ± 61.561 | -25.51 ± 42.198 | -53.78 ± 45.488 |
| 28 day change in Post-meal Glucose Level | -15.98 ± 33.966 | 10.56 ± 44.944 | -34.25 ± 77.268 | -50.33 ± 60.756 |
Change in meal tolerance test insulin area under the curve (0-2 hr) from Day 1 to Day 28 for fixed-dose leucine and metformin combination treatments.
| h*ulU/ml | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Plasma Insulin Absolute | -0.19 ± 74.531 | -5.64 ± 31.360 | -9.59 ± 34.987 | -18.06 ± 35.473 |
| Plasma Insulin Incremental | 4.18 ± 67.120 | -4.25 ± 29.514 | -9.99 ± 27.956 | -15.91 ± 26.720 |
Effect on fasting plasma insulin concentrations across fixed-dose leucine and metformin combination treatments or the standard metformin reference treatment was evaluated.
| h*uIU/mL | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Change From Baseline to Day 28 in Fasting Plasma Insulin Concentration | -2.06 ± 6.652 | -0.74 ± 4.069 | 0.20 ± 7.278 | -1.03 ± 7.694 |
Collected over 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| FDC125 | 0/24 (0%) | 1/24 (4.2%) | 3/24 (12.5%) |
| FDC250 | 0/25 (0%) | 1/25 (4%) | 3/25 (12%) |
| FDC500 | 0/24 (0%) | 0/24 (0%) | 3/24 (12.5%) |
| Control | 0/23 (0%) | 1/23 (4.3%) | 5/23 (21.7%) |
| Event | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 0/24 | 0/25 | 0/24 | 1/23 |
| Suicidal IdeationPsychiatric disorders | 1/24 | 0/25 | 0/24 | 0/23 |
| Lacunar InfarctionInfections and infestations | 0/24 | 1/25 | 0/24 | 0/23 |
| Event | FDC125 | FDC250 | FDC500 | Control |
|---|---|---|---|---|
| Gastric DisordersGastrointestinal disorders | 3/24 | 3/25 | 2/24 | 5/23 |
| InfectionsInfections and infestations | 2/24 | 1/25 | 3/24 | 2/23 |
| DisordersMusculoskeletal and connective tissue disorders | 0/24 | 1/25 | 3/24 | 2/23 |
| Abdominal DistensionGeneral disorders | 0/24 | 0/25 | 0/24 | 2/23 |
| FoodMetabolism and nutrition disorders | 2/24 | 0/25 | 0/24 | 0/23 |
| Respiratory DisordersRespiratory, thoracic and mediastinal disorders | 2/24 | 1/25 | 0/24 | 0/23 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/24 | 0/25 | 2/24 | 0/23 |
| HyperglycemiaEndocrine disorders | 2/24 | 0/25 | 0/24 | 0/23 |
| Nervous DisordersNervous system disorders | 0/24 | 2/25 | 0/24 | 0/23 |
Subjects who had adequate exposure to the randomized study medication during the 4-week treatment period (Day 1/Visit 4 to Day 28/Visit 7) and had adequately complied with the protocol as assessed by the sponsor prior to database lock.The groups in Metformin experience are mutually exclusive.
| Age, Continuous(years) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 53.6 ± 9.87 | 55.1 ± 8.3 | 56.1 ± 10.08 | 59.3 ± 9.64 | 56.0 ± 9.56 |
| Age, Customized(Participants) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| <65 years | 19 | 21 | 18 | 17 | 75 |
| ≥65 years | 5 | 4 | 6 | 6 | 21 |
| Sex: Female, Male(Participants) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| Female | 15 | 13 | 13 | 10 | 51 |
| Male | 9 | 12 | 11 | 13 | 45 |
| Ethnicity (NIH/OMB)(Participants) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 14 | 15 | 12 | 12 | 53 |
| Not Hispanic or Latino | 10 | 10 | 12 | 11 | 43 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 | 6 | 16 |
| White | 22 | 20 | 19 | 16 | 77 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Weight(kg) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 87.049 ± 17.3747 | 88.584 ± 19.4687 | 84.493 ± 19.8622 | 86.777 ± 16.5700 | 86.745 ± 18.1696 |
| Body Mass Index (BMI)(kg/m^2) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 31.142 ± 4.7113 | 30.985 ± 5.5766 | 29.927 ± 5.1504 | 31.146 ± 4.5838 | 30.798 ± 4.9778 |
| Fasting Plasma Glucose(mg/dL) | FDC125 | FDC250 | FDC500 | Control | Total |
|---|---|---|---|---|---|
| Mean | 194.3 ± 50.86 | 170.3 ± 44.28 | 182.8 ± 40.97 | 184.7 ± 50.87 | 182.9 ± 46.93 |
2 further baseline measures are reported on the registry.
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Jul 2014, a primary completion of Aug 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2018, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
NuSirt Biopharma